Solu Therapeutics, a precision-medicine company, announces the appointment of Dr. Philip J. Vickers as its new President and CEO. Dr. Vickers, with over 30 years of biopharma experience, will lead the company’s efforts in developing therapeutics to combat disease-driving cells, focusing on their proprietary CyTaC platform.
Key Highlights
- Dr. Philip J. Vickers succeeds David Donabedian, Ph.D., the Co-founder and start-up CEO of Solu Therapeutics.
- Dr. Vickers brings over three decades of experience in the biopharma sector.
- Solu Therapeutics is working on its CyTaC platform, aiming to revolutionize the treatment of cancer and immune-mediated diseases.
- Dr. Vickers has held significant roles at Merck Research Laboratories, Pfizer, Boehringer-Ingelheim, Resolvyx Pharmaceuticals, Shire Pharmaceuticals, Northern Biologics, and Faze Medicines.
- Solu Therapeutics recently secured an oversubscribed $31 million seed financing.
Source: Business Wire
Notable Quotes
- “Solu is building a new generation of medicines that combine the strengths of biologics and small molecules to advance the way we treat cancer and immune-mediated illnesses. I am thrilled to be leading this dedicated team.” – Dr. Philip J. Vickers, President & CEO at Solu Therapeutics
- “Dr. Vickers’ work supporting the approval of numerous drugs and his deep knowledge of novel therapeutics and clinical development make him the ideal choice to do so. I have the utmost confidence in his ability to advance Solu’s science and lead the team.” – Dr. Christoph Westphal,Co-Founder & General Partner at Longwood Fund
SoH's Take
The appointment of Dr. Philip J. Vickers as the new CEO of Solu Therapeutics is a strategic move that brings a wealth of experience to the company. Dr. Vickers’ extensive background in the biopharma sector, combined with his leadership roles in various renowned companies, positions Solu Therapeutics for significant advancements in the field of precision medicine. The company’s focus on the CyTaC platform, which aims to revolutionize treatments for cancer and immune-mediated diseases, is promising. With the recent seed financing and the new leadership, Solu Therapeutics is poised for growth and innovation in the coming years.
